Raid Aljumaily to Class I Phosphatidylinositol 3-Kinases
This is a "connection" page, showing publications Raid Aljumaily has written about Class I Phosphatidylinositol 3-Kinases.
Connection Strength
0.184
-
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clin Cancer Res. 2021 01 15; 27(2):447-459.
Score: 0.184
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.